NEWS
PROALT awarded with the Prize for the BEST BIOTECHNOLOGICAL STARTUP
Protein Alternatives SL (PROALT) received the Prize as the BEST BIOTECHNOLOGICAL STARTUP in the first edition of the #startups #awards of LA RAZON. The event was chaired by the Mayor of Madrid José Luis Martínez-Almeida, who was accompanied by Andrés Navarro, CEO of LA RAZÓN and the director Francisco Marhuenda. This first edition of the Sartup Awards has [...]
ProAlt will attended the 10th International Biotechnology Trade Show BioSpain 2021
September 14th, 2021 ProAlt will be present at BioSpain 2021 from the 29th September to the 1st October and will participate in the one-to-one meetings to present to investors and pharma companies the latest results of its anti-cadherins_RGD therapeutic antibodies in oncology. BioSpain is the 10th International Trade Show & Partnering Event that will take [...]
ProAlt at Swiss Biotech Day in Basel, Switzerland
September 07th, 2021 The Swiss Biotech Day is one of the leading biotechnology conferences in Europe coming back on stage on September 7, 2021 after the worldwide COVID-19 pandemic and will take place at Basel Congress Center. Today, PROALT will present to investors and pharma companies the recent advances with the therapeutic monoclonal antibody PA-0661 [...]
ProAlt selected to participate in the EIC Corporate Day with Merck
September 6th, 2021 Protein Alternatives (ProAlt) was selected by the European Innovation Council Business Acceleration Services to present to Merck its therapeutic antibody PA-0661 in oncology. ProAlt will be one of the 16 selected companies from 10 different countries that will present innovative projects to Merck on September 30. Merck, the multinational Healthcare, Life Science [...]
Protein Alternatives will participate in the XX Pharma-Biotech Cooperation Meeting organized by Farmaindustria
April 12th, 2021 The XX Pharma-Biotech Cooperation Meeting will be a digital event organized by FarmaIndustria in April 28, 2021 where selected projects from the Spanish National Research Council (CSIC) and its spin-offs will be presented to pharmaceutical companies. PROALT was selected to present its most advanced therapeutic product PA-0661, a monoclonal antibody for the [...]